Antacids Ascend: Anticipated Market Value of US$ 11,194.8 Million by 2033

According to Future Market Insights' most recent industry report, the global antacids marketa is estimated to be around It is anticipated that the market will be worth US$6,971.2 million by the end of 2023. After that, it will expand at a 4.9% CAGR to be valued US$ 11,194.8 million by 2033.

Antacids are commonly used due to their affordability and help to reduce inflammation, swelling, and pain. Likewise, changing lifestyles such as unstable eating patterns, sedentary lifestyles, and sleep patterns are favorably influencing market growth. The development of safe and effective raft-forming antacids that have a longer duration of action and higher efficacy is one of the many product advancements that are boosting the market's expansion.

Pharmaceutical manufacturers are concentrating on developing new drug discoveries, formulation of tablets, and different drug dosages. Furthermore, antacids are widely acceptable by several patients as they can be used as an effective medication for clinical conditions. As a result, the antacids market will drive throughout the forecast period.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-18182

Key Takeaways:

Proton pump inhibitors are the leading segment of antacids and hold around 25.3% market value share in 2022, proton pump inhibitors reduce gastroesophageal reflux disorder and also treat stomach ulcers or duodenal. PPI is generally available in the form of tablets or capsules. The tablet segment is set to lead in terms of indication of antacids with a projected market value share of around 25.5% by 2022; generally, tablets of antacids are used to take in conditions like acidity and heartburn. By route of administration, oral is leading in the global antacids market and is expected to continue to do so with a projected CAGR of 4.4% during the forecasted years, with a market share of 64.4% in the year 2022. Gastroesophageal reflux disease holds the highest share in the antacids market, with a market value share of 49.2% and a CAGR of 4.7% during the projected forecasted period. Being overeating, overweight, eating chocolate and spicy foods as well as consuming caffeine and alcohol are some lifestyle choices that may contribute to GERD. Retail pharmacies as a distribution channel are leading in the global antacids market and are expected to continue to do so with a projected CAGR rate of 4.4% during the forecasted years, with a market share of 44.0% in the year 2022. North America is considered the leading region with a value share of 31.2% in 2022, owing to the high prevalence of diseases like GERD and heartburn.

Market Competition

The market for antacids is fragmented, and there exist several local, upcoming, as well as established players within the market. Key players have initiated marketing initiatives to educate the elderly population about the benefits of antacids while also attempting to improve the drugs with different specifications.

On 22 February 2022, Alkem Labs, Omee antacid brand, started a new advertising campaign called ‘Sabko Pata Hai, India Ka Favorite Antacid hai Omee.’ The campaign's objectives are to make India laugh and to spread awareness that Omee is the treatment for all acidity issues. On 20 October 2020, Dr. Reddy's Laboratories Ltd. announced the launching of the re-launch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg. These tablets are used for heartburn prevention and relief from acid reducers.

Key Segments:

By Drug Class:

Proton Pump Inhibitors H2 Antagonist Acid Neutralizers Pro-Motility Agents Anti-H.Pyrolic Drugs Prostaglandin Analogous Others

By Dosage form:

Tablet Capsules Powder Liquid Others

By Route of Administration:

Oral Injectable

By Indication:

Gastroesophageal Reflux Disease Heartburn Peptic Ulcer Others

By Distribution channel:

Retail Pharmacies Hospital Pharmacies Online Pharmacies

By Region: